Bevacizumab, R-Dxd
Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer, Ovarian Neoplasms
Phase III
Not Yet Recruiting
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
Aug 17, 2026
Bevacizumab, Ds-6000A, R-Dxd, Mvasi, Avastin
Fallopian Tube Cancer, Primary Peritoneal Cancer, High-Grade Serous Ovarian Cancer, Endometrioid Epithelial Ovarian
Phase III
Not Yet Recruiting
A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03)
Aug 03, 2026
Carboplatin, Bevacizumab, Gemcitabine, Paclitaxel, Pegylated Liposomal Doxorubicin, R-Dxd, Raludotatug Deruxtecan, Ds-6000A, Mvasi, Avastin
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Phase III
Not Yet Recruiting
A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)
Jul 29, 2026
―
Trastuzumab Deruxtecan, Trastuzumab, Palbociclib, Endocrine Therapy, Pertuzumab, T-Dxd, Enhertu, Herceptin, Ibrance
Advanced Breast Cancer, Metastatic Breast Cancer, Her2 Positive, Hr Positive
Phase III
Not Yet Recruiting
T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd
Jun 25, 2026
Datopotamab Deruxtecan, Dexamethasone Mouthwash
Stomatitis
Phase IV
Recruiting
An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.
Jan 21, 2026
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Daiichi Sankyo Company Limited (4568N) have in its pipeline
4568N is currently developing the following drugs: Bevacizumab, R-Dxd, Bevacizumab, Ds-6000A, R-Dxd, Mvasi, Avastin, Carboplatin, Bevacizumab, Gemcitabine, Paclitaxel, Pegylated Liposomal Doxorubicin, R-Dxd, Raludotatug Deruxtecan, Ds-6000A, Mvasi, Avastin. These drug candidates are in various stages of clinical development as the company works toward FDA approval.